Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2997998 | 0.84 | NFKB1 (0.31) | TSHRNFKB1CYP2C19 | |
| SCHEMBL10170023 | 0.84 | TSHR (0.38) | TSHRNFKB1CYP2C19 | |
| SCHEMBL6261365 | 0.82 | DNM1 (0.33) | TSHR | |
| SCHEMBL10170322 | 0.79 | TSHR (0.35) | TSHRNFKB1CYP2C19 | |
| SCHEMBL10170323 | 0.77 | TSHR (0.34) | TSHRNFKB1CYP2C19 | |
| SCHEMBL10171052 | 0.77 | TSHR (0.34) | TSHRNFKB1CYP2C19 | |
| SCHEMBL8476820 | 0.77 | TSHR (0.34) | TSHRNFKB1CYP2C19 | |
| SCHEMBL10171050 | 0.77 | TSHR (0.34) | TSHRNFKB1CYP2C19 | |
| SCHEMBL2494457 | 0.75 | TSHR (0.38) | TSHRNFKB1CYP2C19 | |
| SCHEMBL1929167 | 0.75 | TSHR (0.33) | TSHRNFKB1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238676-B2 | Purine derivatives | PFIZER INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238676-B2 | Purine derivatives | PFIZER INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238676-B2 | Purine derivatives | PFIZER INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-6921753-B2 | Purine derivatives | PFIZER INC (US) | 2005-07-26 | — | — | US | disclosed |
| US-20040229838-A1 | Purine derivatives | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| EP-1438046-A4 | THIAZOLE BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION, AND METHODS FOR THEIR USE | AGOURON PHARMA (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1438046-A2 | THIAZOLE BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2004-07-21 | — | — | EP | disclosed |
| EP-1296996-B1 | PURINE DERIVATIVES | PFIZER LTD (GB) | 2004-05-26 | — | — | EP | disclosed |
| US-6720346-B2 | (4-AMINOTHIAZOL-2-YLAMINO)-BENZAMIDE COMPOUNDS; PROTEIN KINASE INHIBITORS; CANCER; AUTOIMMUNE, VIRAL, FUNGAL, NEURODEGENERATIVE, AND CARDIOVASCULAR DISORDERS | AGOURON PHARMACEUTICALS, INC. | 2004-04-13 | — | — | US | disclosed |
| US-20030225147-A1 | Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use | AGOURON PHARMACEUTICALS INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1296996-A1 | PURINE DERIVATIVES | Pfizer Limited (GB) | 2003-04-02 | — | — | EP | disclosed |
| WO-2003004467-A2 | THIAZOLE BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2003-01-16 | — | — | WO | disclosed |
| US-20020032168-A1 | Purine derivatives | PFIZER INC. | 2002-03-14 | — | — | US | disclosed |
| WO-2002000676-A1 | PURINE DERIVATIVES | PFIZER LIMITED (GB) | 2002-01-03 | — | — | WO | disclosed |
| US-4629739-A | Substituted sulfonamidobenzamides and method of treating arrhythmias | SCHERING A.G. (DE) | 1986-12-16 | — | — | US | disclosed |
| EP-0158775-A1 | Substituted sulfonamidobenzamides, antiarrythmic agents and compositions thereof | SCHERING AKTIENGESELLSCHAFT (DE) | 1985-10-23 | — | — | EP | disclosed |
| US-4544654-A | Substituted sulfonamidobenzamides, antiarrhythmic agents and compositions thereof | SCHERING A.G. (DE) | 1985-10-01 | — | — | US | disclosed |
| US-4309546-A | Piperidino pyrrolidinones | CIBA-GEIGY CORPORATION (US) | 1982-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229838-A1 | Purine derivatives | ADORA2A, ADORA1, ADORA3 | TSHR 646/4885NFKB1 2443/4885CYP2C19 376/4885 |
| US-20030225147-A1 | Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use | TK1, MKI67, CDKN1A | TSHR 2198/4885NFKB1 1458/4885CYP2C19 193/4885 |
| US-20020032168-A1 | Purine derivatives | ADORA2A, ADORA1, ADORA3 | TSHR 646/4885NFKB1 2443/4885CYP2C19 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.